Payment overview · 2025
General Payments
$518.72
21 reported records · 8 companies
Healthcare provider profile · identity verified
Matthew F Browning, M.D
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGFIELD, TN · NPI 1679667521
Verified facts
What the public records show
CMS Open Payments records show Matthew F Browning, M.D received $518.72 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $183.13 | 35.3% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $156.05 | 30.1% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.13 | 9.1% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $37.31 | 7.2% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $29.66 | 5.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.90 | 4.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.49 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.05 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $518.72 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $165.09 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $119.90 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $119.90 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.39 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $61.35 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $47.13 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $37.31 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.15 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $29.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 18 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 402 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 119 |
| Lisinopril | Lisinopril | 358 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 93 |
| Simvastatin | Simvastatin | 315 | 80 |
| Alprazolam | Alprazolam | 298 | 60 |
| Gabapentin | Gabapentin | 268 | 61 |
| Losartan Potassium | Losartan Potassium | 267 | 82 |
| Meloxicam | Meloxicam | 238 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 48 |
| Metformin Hcl Er | Metformin Hcl | 164 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 43 |
| Prednisone | Prednisone | 153 | 118 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 40 |
| Potassium Chloride | Potassium Chloride | 138 | 32 |
| Metformin Hcl | Metformin Hcl | 135 | 38 |
| Trazodone Hcl | Trazodone Hcl | 134 | 26 |
| Fenofibrate | Fenofibrate | 132 | 31 |
| Montelukast Sodium | Montelukast Sodium | 132 | 34 |
| Furosemide | Furosemide | 131 | 35 |
| Sertraline Hcl | Sertraline Hcl | 126 | 32 |
| Glimepiride | Glimepiride | 123 | 28 |
| Memantine Hcl | Memantine Hcl | 115 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 112 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 19 |
| Famotidine | Famotidine | 106 | 35 |
| Clonazepam | Clonazepam | 104 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 32 |
| Xarelto | Rivaroxaban | 98 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 18 |
| Carvedilol | Carvedilol | 87 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 29 |
| Amoxicillin | Amoxicillin | 78 | 57 |
| Lorazepam | Lorazepam | 78 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 20 |
| Allopurinol | Allopurinol | 76 | 21 |
| Ozempic | Semaglutide | 71 | 11 |
| Azithromycin | Azithromycin | 68 | 54 |
| Lovastatin | Lovastatin | 68 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 13 |
| Chlorthalidone | Chlorthalidone | 62 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 16 |
| Atenolol | Atenolol | 54 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 42 |
| Farxiga | Dapagliflozin Propanediol | 51 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 18 |
| Ibuprofen | Ibuprofen | 49 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 15 |
| Glipizide | Glipizide | 47 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 13 |
| Temazepam | Temazepam | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | 12 |
| Alendronate Sodium | Alendronate Sodium | 43 | 12 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Meclizine Hcl | Meclizine Hcl | 40 | 18 |
| Donepezil Hcl | Donepezil Hcl | 38 | 12 |
| Benazepril Hcl | Benazepril Hcl | 37 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | 12 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Nystatin | Nystatin | 35 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 19 |
| Eliquis | Apixaban | 34 | 13 |
| Ketoconazole | Ketoconazole | 34 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 11 |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 12 |
| Topiramate | Topiramate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Etodolac | Etodolac | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Benzonatate | Benzonatate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $518.72 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, BREZTRI, Cologuard Collection Kit, FARXIGA, Ozempic, PAXLOVID, QULIPTA, Rybelsus, SHINGRIX, SKYCLARYS, UBRELVY, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error